172.[20230208]Regenerative medicine applications 1
페이지 정보
작성자 신호식 작성일23-02-03 14:24 조회504회 댓글0건관련링크
- https://youtu.be/jehVW5lwZIk 488회 연결
본문
첨부한 자료(유튜브 클립, 참고문헌 등)를 학문적 목적으로만 사용해 주시길 부탁드립니다
Review Front Bioeng Biotechnol
. 2022 Nov 25;10:942750. doi: 10.3389/fbioe.2022.942750. eCollection 2022.
Regenerative medicine applications: An overview of clinical trials
Astgik Petrosyan 1, Paulo N Martins 2, Kim Solez 3, Basak E Uygun 4, Vijay S Gorantla 5, Giuseppe Orlando 5
Affiliations expand
PMID: 36507264 PMCID: PMC9732032 DOI: 10.3389/fbioe.2022.942750
Free PMC article
Abstract
Insights into the use of cellular therapeutics, extracellular vesicles (EVs), and tissue engineering strategies for regenerative medicine applications are continually emerging with a focus on personalized, patient-specific treatments. Multiple pre-clinical and clinical trials have demonstrated the strong potential of cellular therapies, such as stem cells, immune cells, and EVs, to modulate inflammatory immune responses and promote neoangiogenic regeneration in diseased organs, damaged grafts, and inflammatory diseases, including COVID-19. Over 5,000 registered clinical trials on ClinicalTrials.gov involve stem cell therapies across various organs such as lung, kidney, heart, and liver, among other applications. A vast majority of stem cell clinical trials have been focused on these therapies' safety and effectiveness. Advances in our understanding of stem cell heterogeneity, dosage specificity, and ex vivo manipulation of stem cell activity have shed light on the potential benefits of cellular therapies and supported expansion into clinical indications such as optimizing organ preservation before transplantation. Standardization of manufacturing protocols of tissue-engineered grafts is a critical first step towards the ultimate goal of whole organ engineering. Although various challenges and uncertainties are present in applying cellular and tissue engineering therapies, these fields' prospect remains promising for customized patient-specific treatments. Here we will review novel regenerative medicine applications involving cellular therapies, EVs, and tissue-engineered constructs currently investigated in the clinic to mitigate diseases and possible use of cellular therapeutics for solid organ transplantation. We will discuss how these strategies may help advance the therapeutic potential of regenerative and transplant medicine.
Keywords: COVID-19; bioengineering; extracellular vesicles; regenerative medicine; stem cells; tissue engineering; transplantation.
Review Front Bioeng Biotechnol
. 2022 Nov 25;10:942750. doi: 10.3389/fbioe.2022.942750. eCollection 2022.
Regenerative medicine applications: An overview of clinical trials
Astgik Petrosyan 1, Paulo N Martins 2, Kim Solez 3, Basak E Uygun 4, Vijay S Gorantla 5, Giuseppe Orlando 5
Affiliations expand
PMID: 36507264 PMCID: PMC9732032 DOI: 10.3389/fbioe.2022.942750
Free PMC article
Abstract
Insights into the use of cellular therapeutics, extracellular vesicles (EVs), and tissue engineering strategies for regenerative medicine applications are continually emerging with a focus on personalized, patient-specific treatments. Multiple pre-clinical and clinical trials have demonstrated the strong potential of cellular therapies, such as stem cells, immune cells, and EVs, to modulate inflammatory immune responses and promote neoangiogenic regeneration in diseased organs, damaged grafts, and inflammatory diseases, including COVID-19. Over 5,000 registered clinical trials on ClinicalTrials.gov involve stem cell therapies across various organs such as lung, kidney, heart, and liver, among other applications. A vast majority of stem cell clinical trials have been focused on these therapies' safety and effectiveness. Advances in our understanding of stem cell heterogeneity, dosage specificity, and ex vivo manipulation of stem cell activity have shed light on the potential benefits of cellular therapies and supported expansion into clinical indications such as optimizing organ preservation before transplantation. Standardization of manufacturing protocols of tissue-engineered grafts is a critical first step towards the ultimate goal of whole organ engineering. Although various challenges and uncertainties are present in applying cellular and tissue engineering therapies, these fields' prospect remains promising for customized patient-specific treatments. Here we will review novel regenerative medicine applications involving cellular therapies, EVs, and tissue-engineered constructs currently investigated in the clinic to mitigate diseases and possible use of cellular therapeutics for solid organ transplantation. We will discuss how these strategies may help advance the therapeutic potential of regenerative and transplant medicine.
Keywords: COVID-19; bioengineering; extracellular vesicles; regenerative medicine; stem cells; tissue engineering; transplantation.